Topical and oralretinoids, derivatives of vitamin A, are commonly prescribed to treat severe acne and psoriasis ... the integrity of skin and mucosal cells, which act as the body’s first ...

plaque psoriasis, Crohn's disease and ulcerative colitis — causing inflammation and tissue destruction in joints, mucosa or skin. In some cases of autoimmune disease, the immune system damages the ...

Both HVs and UC patients were excluded if they had a history of psoriasis, psoriatic arthritis ... of efmarodocokin alfa treatment on intestinal gene expression profiles and mucosal microbiota, ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Mucosal immunology is the study of immune responses that occur at mucosal surfaces, such as the intestines, the urogenital tract and the lungs. These tissues are closely associated with the ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

They will inspect the vaginal walls, vaginal opening, and mucosal tissues, and may ask a person to bear down or strain. A person may not require treatment if the cystocele is not causing symptoms ...

Generalized pustular psoriasis is a very rare and extreme form of psoriasis. It’s characterized by reoccurring flare-ups that cause pus-filled bumps and red or discolored skin over a large part ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Tuberculosis (TB) is a bacterial infection that usually affects the lungs but can spread to other parts of the body, including the skin. Once it reaches the skin, TB can cause a variety of lesions ...

AAD 2025 IL-23 Inhibitors Tested for Expanded Role in Psoriasis In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions ...